Post-earnings recap
Reported
Wed, May 1, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a 7.06% decline in stock price following the earnings announcement. The lack of revenue figures and forward guidance may have further unsettled investors. Management's defensive tone suggests ongoing challenges that could impact future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.42 | N/A | +22.69% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current market conditions impacting performance. They remain focused on strategic initiatives to drive future growth.
Management highlighted ongoing challenges in achieving profitability.
They emphasized a focus on long-term growth despite short-term setbacks.